Deep Brain Capital
Backing brain breakthroughs across modalities
- Biotech
- Neurotech
- Digital health
- Platforms
The gap
3.4 billion PEOPLE
…living with a neurological condition: leading cause of ill health and disability worldwide
(GBD 2021, Lancet Neurology 2024)
The convergence thesis
For patient and investor, future value lives in cross-modality innovation
-
01
Biotech CNS
Disease-modifying therapeutics.
Neurodegeneration, rare CNS and psychiatry, etc, with emphasis on crossing the blood–brain barrier
-
02
Neurotech
Measuring and modulating the brain.
Brain–computer interfaces, closed-loop neuromodulation, focused ultrasound, next-generation neuro-imaging
-
03
Digital health
Decoding & interfacing with neural data.
AI-native diagnostics, digital & cognitive biomarkers and SaMD for diagnosis, treatment decisions, surgical planning
-
04
Platforms & tools
Building blocks for discovery & development.
NeuroAI, organ-on-a-chip, discovery platforms, TechBio, AI-enabled databanks, Foundational models
Framework
Investing quality, from start to exit
-
01
Focus
Seed to Series A
-
02
Sourcing
Collaboration with key incubators/accelerators
-
03
Evaluation
Leading academic & industry advisors
-
04
Support
Continued access to global expertise
Team
-
Nicolas Roberti de Winghe
Managing Partner
Founder and former managing partner of TCD Capital (€60M AuM), leading life science investments; UBS wealth and structured products
-
Ugo Tomasello, PhD, MBA
General Partner
Molecular neurobiologist; Novartis and GSK; investor at Masawa and CVX Ventures.
-
Eugénie Suter, MD, PhD
General Partner
Fmr Roche Medical Director, Neuroscience and Rare Diseases. Euro-US hybrid.
-
Michel Vounatsos, MD
Chairman
Former CEO of Biogen (global CNS pharma, $10B+ revenue). Prior senior leadership at Merck.
-
Current interns
Lorenzo Ghezzi
PhD, neuroscience